NYSE$CVS
CVS Health Corp · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
CVS Health's Q2 2020 performance was marked by strong enterprise results, driven by diversified assets amidst the COVID-19 pandemic. The company raised its full-year EPS and cash flow guidance.
CVS Health reported a 3.0% increase in total revenues, reaching $65.3 billion. GAAP operating income increased by 40.5% to $4.7 billion, and adjusted operating income increased by 32.2% to $5.3 billion. GAAP diluted earnings per share was $2.26, and adjusted EPS was $2.64.
- Total revenues increased by 3.0% to $65.3 billion, driven by growth across all segments.
- GAAP operating income increased by 40.5% to $4.7 billion, and adjusted operating income increased by 32.2% to $5.3 billion.
- GAAP diluted earnings per share reached $2.26, and adjusted EPS was $2.64.
- The company raised its full-year 2020 GAAP diluted EPS guidance range to $5.59 to $5.72 and adjusted EPS guidance range to $7.14 to $7.27.
Headline financials
Revenue & EPS history
CVS Health · Revenue · Quarterly
$65.3B
Revenue by segment
CVS Health · $102B total across 3 segments · Q3 2023
- Health Services$46.9B+8.5%45.9%
- Pharmacy & Consumer Wellness$28.9B+8.1%28.3%
- Health Care Benefits$26.3B+16.8%25.8%
Forward guidance
CVS Health raised its full year 2020 GAAP diluted EPS guidance range to $5.59 to $5.72 from $5.47 to $5.60 and its full year 2020 Adjusted EPS guidance range to $7.14 to $7.27 from $7.04 to $7.17 and also raised its full year 2020 cash flow from operations guidance range to $11.0 billion to $11.5 billion from $10.5 billion to $11.0 billion.
Tailwinds
- Raised GAAP diluted EPS guidance range to $5.59 to $5.72 from $5.47 to $5.60
- Raised Adjusted EPS guidance range to $7.14 to $7.27 from $7.04 to $7.17
- Raised cash flow from operations guidance range to $11.0 billion to $11.5 billion from $10.5 billion to $11.0 billion
- Projects higher utilization in its Health Care Benefits segment in the second half of 2020 than in the first half of 2020
- Reflects an update to its estimated full year effective income tax rate
Headwinds
- Acknowledges the inherent and unprecedented uncertainty surrounding the ongoing COVID-19 pandemic and its impact
- Projects continued significant COVID-19 related investments, including operating costs, in the remainder of the year.
- Risks and uncertainties related to the COVID-19 pandemic
- The pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns
- The timing, scope and impact of stimulus legislation and other federal, state and local governmental responses to the pandemic
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.1%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+1.3%
Avg return
30 days after
56%
41 / 73 earnings
Positive
+14.9%
Q4 2024
Best reaction
-18.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +14.3% | +19.1% | |
| Q4 2025 | -0.1% | +3.6% | +0.4% | |
| Q3 2025 | -1.9% | -4.6% | -2.2% | |
| Q2 2025 | -0.3% | +1.8% | +17.4% | |
| Q1 2025 | +4.1% | -0.7% | -4.0% | |
| Q4 2024 | +14.9% | +19.7% | +19.4% | |
| Q3 2024 | +3.1% | +0.8% | -0.1% | |
| Q2 2024 | -0.8% | -4.3% | -1.0% | |
| Q1 2024 | -18.5% | -17.3% | -12.0% | |
| Q4 2023 | +1.8% | +4.8% | +1.8% | |
| Q3 2023 | +0.9% | +3.0% | -0.8% | |
| Q2 2023 | +0.5% | -0.1% | -11.2% | |
| Q1 2023 | -5.5% | -4.2% | -3.8% | |
| Q4 2022 | +4.8% | +4.5% | -10.3% | |
| Q3 2022 | +3.4% | +6.9% | +8.4% | |
| Q2 2022 | +6.8% | +7.0% | +4.3% | |
| Q1 2022 | +1.8% | +3.0% | -1.1% | |
| Q4 2021 | -5.0% | -7.1% | -6.6% | |
| Q3 2021 | +3.7% | +2.9% | -0.3% | |
| Q2 2021 | -4.7% | -2.8% | +4.1% | |
| Q1 2021 | +6.9% | +9.6% | +12.1% | |
| Q4 2020 | -2.0% | -5.1% | +0.4% | |
| Q3 2020 | +10.0% | +13.2% | +21.3% | |
| Q2 2020 | -1.3% | +1.1% | -7.3% | |
| Q1 2020 | +0.4% | +4.3% | +11.7% | |
| Q4 2019 | -2.5% | -3.4% | -19.2% | |
| Q3 2019 | +6.6% | +6.6% | +11.9% | |
| Q2 2019 | +9.2% | +8.6% | +15.0% | |
| Q1 2019 | +4.3% | +4.1% | -3.7% | |
| Q4 2018 | -10.8% | -12.4% | -19.8% | |
| Q3 2018 | +6.9% | +8.3% | +3.9% | |
| Q2 2018 | +4.8% | +6.2% | +18.1% | |
| Q1 2018 | -8.4% | -9.2% | -5.8% | |
| Q4 2017 | -6.7% | -5.7% | -6.8% | |
| Q3 2017 | -0.4% | +2.5% | +3.1% | |
| Q2 2017 | +0.4% | +0.4% | +1.6% | |
| Q1 2017 | -2.8% | -1.1% | -4.5% | |
| Q4 2016 | +1.9% | +2.1% | +4.4% | |
| Q3 2016 | -8.2% | -10.0% | -6.3% | |
| Q2 2016 | +4.2% | +4.2% | -0.1% | |
| Q1 2016 | +2.4% | — | — | |
| Q4 2015 | +3.9% | — | — | |
| Q3 2015 | -3.3% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +3.0% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +2.6% | — | — | |
| Q4 2013 | +2.4% | — | — | |
| Q3 2013 | +3.0% | — | — | |
| Q2 2013 | -4.1% | — | — | |
| Q1 2013 | +1.3% | — | — | |
| Q4 2012 | -1.0% | — | — | |
| Q3 2012 | +0.1% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | +2.9% | — | — | |
| Q4 2011 | -1.2% | — | — | |
| Q3 2011 | +6.3% | — | — | |
| Q2 2011 | -5.7% | — | — | |
| Q1 2011 | +3.9% | — | — | |
| Q4 2010 | -0.2% | — | — | |
| Q4 2007 | -0.2% | — | — | |
| Q3 2010 | +3.2% | — | — | |
| Q2 2010 | -2.7% | — | — | |
| Q1 2009 | -2.8% | — | — | |
| Q1 2010 | -2.2% | — | — | |
| Q4 2009 | +1.2% | — | — | |
| Q3 2008 | -17.6% | — | — | |
| Q3 2009 | -17.6% | — | — | |
| Q4 2008 | +1.1% | — | — | |
| Q2 2008 | +1.1% | — | — | |
| Q2 2009 | +1.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro